<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00264654</url>
  </required_header>
  <id_info>
    <org_study_id>PIR104777</org_study_id>
    <nct_id>NCT00264654</nct_id>
  </id_info>
  <brief_title>Long-term Study Of Paroxetine in Women and Men</brief_title>
  <acronym>SAD</acronym>
  <official_title>Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Social Phobia/Social Anxiety Disorder (SAD) -A Open-Label, Uncontrolled, Long-term Study- &lt;Phase III Study&gt;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the efficacy and safety in Social Anxiety Disorder (SAD)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">November 2005</completion_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the LSAS total score at week 52 (Score at week 52- Score at week 0)</measure>
    <time_frame>52 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients responding with a CGI Global Improvement Item. Change from baseline in the CGI Severity of Illness score. Change from baseline in the HAM-D total score. Proportion of patients continuing treatment.</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">50</enrollment>
  <condition>Social Phobia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BRL29060A</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paroxetine hydrochloride hydrate</intervention_name>
    <other_name>BRL29060A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Diagnosis of Social Anxiety Disorder (SAD) (300.23 Social Phobia/Social Anxiety
             Disorder) according to DSM-IV-TR criteria.

          -  Must give a written informed consent.

          -  If the patient is under 20, both the patient himself/herself and his/her proxy
             consenter must give written informed consent.

          -  Patients have a minimum score of 60 on the LSAS total score.

        Exclusion criteria:

          -  Patients primarily diagnosed with a disorder that is categorized into Axis I excluding
             SAD by DSM-IV-TR (e.g. major depression, dysthymic disorder, specific phobia (simple
             phobia) , obsessive compulsive disorder, panic disorder) within 24 weeks before week
             -2.

          -  Patients with a history or complication of schizophrenia and bipolar disorder

          -  Patients with a complication of body dysmorphic disorder.

          -  Patients with evidence of substance abuse (alcohol or drugs).

          -  substance dependence by DSM-IV-TR criteria within 24 weeks before week -2.

          -  Patients who started psychotherapy and cognitive-behavioural therapy within 24 weeks
             before week-2, except for supportive psychotherapy.

          -  Patients receiving electro-convulsive therapy (ECT) within 12 weeks before week -2.

          -  Patients being pregnant, lactating or are of childbearing potential and are likely to
             become pregnant.

          -  Patients with 3 or more points of HAM-D Item No. 3, or who are likely to attempt
             suicide.

          -  Patients with a history or complication of cancer or malignant tumor.

          -  Patients receiving MAO inhibitors (FPÂ®) within 14 days before expected week 0 visit
             date.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saitama</city>
        <zip>332-0012</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>194-0022</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2005</study_first_submitted>
  <study_first_submitted_qc>December 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2005</study_first_posted>
  <last_update_submitted>April 11, 2013</last_update_submitted>
  <last_update_submitted_qc>April 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Social</keyword>
  <keyword>(SAD)</keyword>
  <keyword>Anxiety</keyword>
  <keyword>Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phobic Disorders</mesh_term>
    <mesh_term>Phobia, Social</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paroxetine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

